Gastric cancer
Conditions
Interventions
Sponsors
Heping Hospital Affiliated to Changzhi Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, aged 18 to 70 years; 2. D2 lymph node dissection has been performed for gastric cancer and gastroesophageal junction adenocarcinoma, without gross or microscopic residual tumor (i.e. R0 resection); 3. Postoperative pathological stages were III stage gastric cancer and gastroesophageal junction adenocarcinoma; 4. In good general condition, ECOG PS: 0-1 points; 5. Baseline blood routine and biochemical indicators meet the following standards: (1) Hemoglobin >= 9.0 g/dL; (2) Absolute count of neutrophils (ANC) >=1,500/mm^3; (3) platelet count >=100,000/mm^3; (4) Total bilirubin =2+, 24h urine protein quantitative protein must be =3 months; 9. Women of childbearing age must have a pregnancy test (serum or urine) within 7 days prior to enrolment, be negative, and be willing to use an appropriate method of contraception during the trial and 8 weeks after the last administration of the test drug.For men, surgical sterilization or consent to use an appropriate method of contraception during the trial and for 8 weeks after the last administration of the experimental drug; 10. Subjects volunteered to participate in this study, signed informed consent, and showed good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. People who have been confirmed to be allergic to apatinib, tiggio and oxaliplatin; 2. Patients with hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); 3. Multiple factors that may affect oral medication (such as inability to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction); 4. Patients with a definite tendency of gastrointestinal bleeding, including the following conditions: local active ulcer lesions, and fecal occult blood (++) was not included in the group;Patients with a history of melena or hematemesis within 2 months; Gastroendoscopy is required for stool occult blood (+) without surgical resection of the primary lesion of the gastric tumor, such as ulcerative gastric cancer, and the major investigator believes that massive gastrointestinal bleeding may occur; 5. Patients have previously received any targeted therapy; 6. Postoperative pathology showed positive margin; 7. Patients with internal systemic diseases and psychiatric diseases are not suitable for radiotherapy or chemotherapy; 8. Patients with acute infection requiring antibiotic treatment; 9. Patients who have participated in clinical trials of other drugs within four weeks; 10. Patients with concomitant diseases that, in the Investigator's judgment, seriously endanger patient safety or affect patient completion of the study; 11. Patients considered unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival at 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year recurrence rate;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactZhao Qiang
Heping Hospital Affiliated to Changzhi Medical College
Outcome results
None listed